Welcome Guest | Register / Login

The US Onychomycosis Market: Size, Trends & Forecasts (2016-2020)

Table of Contents

1. Executive Summary

2. Introduction
2.1 Onychomycosis: An Overview
2.1.1 Signs and Symptoms
2.1.2 Causes of Onychomycosis
2.2 Types of Onychomycosis
2.3 Treatment For Onychomycosis

3. US Market Analysis
3.1 US Onychomycosis Market by Prevalence
3.1.1 US Onychomycosis Market by Prevalence
3.1.2 US Onychomycosis Market Prevalence by Segments
3.2 US Nail Care Market: An Analysis
3.2.1 US Nail Care Market by Value
3.2.2 US Nail Care Market by Segments
3.2.3 US Nail Care Market Value by Major Drugs
3.2.4 US Nail Care Market Volume by Major Drugs
3.3 US Kerydin Drug Market: An Anlalysis
3.3.1 US Kerydin Drug Market by Value
3.3.2 US Kerydin Drug Market by Volume
3.3.3 US Kerydin Drug Market by Average Price
3.4 US Jublia Drug Market: An Analysis
3.4.1 US Jublia Drug Market by Value
3.4.2 US Jublia Drug Market by Volume
3.4.3 US Jublia Drug Market by Average Price
3.5 US Generic Drugs Market: An Analysis
3.5.1 US Generic Drugs Market by Value

4. Market Dynamics
4.1 Growth Drivers
4.1.1 Rising Per-capita Healthcare Expenditure
4.1.2 Increasing Diabetic Patients
4.1.3 Aging Population
4.1.4 Increasing Prevalence of Peripheral Artery Disease (PAD)
4.2 Challenges
4.2.1 Reimbursement
4.2.2 Low Awareness
4.2.3 Side Effects
4.3 Market Trends
4.3.1 Estimated Market for MOB-015
4.3.2 Treatment Comparison
4.3.3 Alternative Treatment
4.3.4 Onychomycosis in Children

5. Competitive Landscape
5.1 Competition in Onychomycosis Prescription Market: An Overview
5.2 Financial Comparison of Major Players of the US Onychomycosis Market

6. Company Profiling
6.1 Valeant Pharmaceuticals
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategy
6.2 Anacor Pharmaceuticals
6.2.1 Business Overview
6.2.2 Financial Overview
6.2.3 Business Strategy
6.3 Johnson & Johnson
6.3.1 Business Overview
6.3.2 Financial Overview
6.3.3 Business Strategy
6.4 Novartis AG
6.4.1 Business Overview
6.4.2 Financial Overview
6.4.3 Business Strategy

List of Tables

Table 1: Treatments Available for Onychomycosis
Table 2: Financial Comparison of Major Players of the US Onychomycosis Market
Table 3: Acquisitions of Valeant Pharmaceuticals

List of Figures

Figure 1: Types of Onychomycosis
Figure 2: Treatment for Onychomycosis
Figure 3: US Onychomycosis Market by Prevalence; 2015 (Million)
Figure 4: US Onychomycosis Market Prevalence by Segments; 2015
Figure 5: US Nail Care Market by Value; Jan14–Jul15 (US$ Million)
Figure 6: US Nail Care Market by Value; Aug15-May16 (US$ Million)
Figure 7: US Nail Care Market by Segments; Dec14 and Jul15
Figure 8: US Nail Care Market Value by Major Drugs; Feb14-May15
Figure 9: US Nail Care Market Volume by Major Drugs; Feb16-May15 (Count’000)
Figure 10: US Kerydin Drug Market by Value; Oct14-July15 (US$ Million)
Figure 11: US Kerydin Drug Market by Volume; Sep14- Jul-15 (Count)
Figure 12: US Kerydin Drug Market by Average Price; Sep14-Jul-15 (US$)
Figure 13: US Jublia Drug Market by Value; Jul14-Jul15 (US$ Million)
Figure 14: US Jublia Drug Market by Volume; Jun14-Jul15 (Count)
Figure 15: US Jublia Drug Market by Average Price; Jun14-Jul15 (US$)
Figure 16: US Generic Drugs Market by Value; 2006-2014
Figure 17:US Per-Capita Healthcare Expenditure; 2007-2014 (US$)
Figure 18: Patients with Diagnosed Diabetes in the US; 2007-2015E (Million)
Figure 19: US Population 65 years & Above; 2007-2015 (Million)
Figure 20: Prevalence of PAD in the US; 2012-2015 (Million)
Figure 21: Estimated Market for MOB-015; 2020-2030 (US$ Million)
Figure 22: Valeant Revenue; 2010-2015 (US$ Billion)
Figure 23: Valeant Revenue by Segments; 2015
Figure 24: Anacor Revenue; 2011-2015 (US$ Million)
Figure 25: Anacor  Research and Development Expense; 2015 (US$ Million)
Figure 26: Johnson & Johnson Total Sales; 2011-2015 (US$ Billion)
Figure 27: Johnson & Johnson Sales by Segments; 2015
Figure 28: Johnson & Johnson Sales by Region; 2015
Figure 29: Novartis AG Total Sales; 2011-2015 (US$ Billion)
Figure 30: Novartis AG Sales by Segments; 2015
Figure 31: Novartis AG Sales by Region; 2015

Single User License: Report will be emailed in PDF format and can be accessed by a specific user. This License type allows the report to be Printed.
Corporate/Global User License: Report will be emailed in PDF format and allows all employees within the organization to access it.  This License type allows the report to be Printed.
Why http://www.marketreportsonline.com/
Published By :Daedal Research
Price